Rezdiffra (Resmetirom) Global Regulatory Status: What Women Need to Know

What Is Rezdiffra and Why Does It Matter for Women?

Rezdiffra (resmetirom) is the first drug the FDA has ever approved specifically to treat MASH (metabolic dysfunction-associated steatohepatitis), a condition previously called NASH (nonalcoholic steatohepatitis). That distinction matters for you. MASH is not simply "fatty liver." It involves active liver cell injury, inflammation, and progressive scarring that can advance to cirrhosis.

Women are not a minority in this disease. Approximately 56% of patients with MASH-related advanced fibrosis in large U.S. Registry cohorts are women, and the hormonal shifts of perimenopause and post-menopause directly accelerate disease progression. The loss of estrogen after menopause reduces hepatic insulin sensitivity and increases visceral fat deposition, both of which worsen steatohepatitis. MASH in women, especially post-menopausal women, has historically been under-diagnosed because clinicians have more often screened men with metabolic syndrome.

Approval of resmetirom gives clinicians a pharmacologic tool for the first time. Understanding exactly what the FDA approved, what the label permits, and what is still unknown for women across different life stages is the purpose of this article.

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. It mimics thyroid hormone action specifically in the liver, where THR-beta receptors are concentrated. By activating THR-beta, resmetirom increases hepatic fat oxidation, reduces lipid synthesis, and lowers liver triglyceride content. It does this without substantially activating THR-alpha receptors in the heart or bone, which is what made earlier thyromimetics unsafe.

Women with hypothyroidism, PCOS, or insulin resistance have altered thyroid signaling that may interact with resmetirom's mechanism. This is discussed further in the sex-specific physiology section below.

FDA Approval: The Timeline and the Label

March 14, 2024: Accelerated and Traditional Approval Combined

On March 14, 2024, the FDA approved resmetirom under both traditional and accelerated approval pathways for adults with noncirrhotic MASH and moderate-to-severe liver fibrosis, specifically fibrosis stages F2 and F3 on histological scoring. The accelerated approval component was based on histological endpoints: resolution of MASH without worsening of fibrosis, or at least a one-stage fibrosis improvement.

The traditional approval component was based on the same MAESTRO-NASH trial data and reflected the FDA's judgment that the histological outcomes are reasonably likely to predict long-term clinical benefit. This dual-pathway designation is clinically significant because it means resmetirom does not carry the same post-market "verify or withdraw" pressure as a purely accelerated-approval drug, though Madrigal Pharmaceuticals is conducting MAESTRO-NASH Outcomes, a cardiovascular and liver outcomes trial, as a post-marketing commitment.

What the Label Says: Doses and Patient Selection

The FDA-approved label specifies two doses based on body weight:

• 80 mg once daily for patients weighing less than 100 kg
• 100 mg once daily for patients weighing 100 kg or more

The drug is taken orally, once daily, with or without food. The label restricts use to patients with histologically confirmed noncirrhotic MASH with fibrosis stages F2 or F3. Patients with cirrhosis (stage F4) were excluded from MAESTRO-NASH and are not covered by the approval.

The full prescribing information also requires hepatic function monitoring because resmetirom is metabolized primarily by CYP2C8 and is a substrate of OATP1B1 and OATP1B3. Drugs that inhibit these transporters, including gemfibrozil and certain rifamycin antibiotics, can significantly raise resmetirom exposure.

The MAESTRO-NASH Trial: Core Evidence

The MAESTRO-NASH trial, published in the New England Journal of Medicine in 2024, enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F3. Patients were randomized to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks.

Key results at 52 weeks:

• MASH resolution without fibrosis worsening: 25.9% with 80 mg, 29.9% with 100 mg, versus 9.7% with placebo (p <0.001 for both doses)
• At least one-stage fibrosis improvement: 24.2% with 80 mg, 25.9% with 100 mg, versus 14.2% with placebo (p <0.001 for both doses)

LDL cholesterol fell by approximately 16% and triglycerides by approximately 22% in the 100 mg arm, a cardiovascular benefit that the FDA acknowledged in labeling. Women with MASH commonly carry elevated triglycerides and atherogenic dyslipidemia, so this secondary benefit is clinically relevant to their cardiovascular risk profile.

Women made up approximately 54% of the MAESTRO-NASH trial population, which is meaningfully higher female representation than most cardiovascular or metabolic trials and gives the efficacy data reasonable applicability to women. Subgroup analyses by sex were not prominently reported, which is a genuine evidence gap discussed in the section on sex-specific physiology.

Global Regulatory Status Outside the United States

European Medicines Agency (EMA)

As of early 2025, the European Medicines Agency is conducting regulatory review of resmetirom. Madrigal Pharmaceuticals submitted a Marketing Authorization Application to the EMA, and the Committee for Medicinal Products for Human Use (CHMP) began its formal assessment. No opinion had been issued as of the date this article was last reviewed. European patients and clinicians should monitor the EMA's medicine registry for updates.

The EMA's assessment will independently evaluate MAESTRO-NASH data and may impose different risk management measures than those required by the FDA, particularly regarding pregnancy prevention programs. The EU has historically required Pregnancy Prevention Programmes (PPPs) for teratogenic or embryotoxic drugs that are more structured than U.S. Labeling warnings alone.

United Kingdom (MHRA)

The Medicines and Healthcare products Regulatory Agency (MHRA) operates independently from the EMA since Brexit. No MHRA approval had been issued for resmetirom as of early 2025. The MHRA has a rolling review process and may consider resmetirom data submitted separately from the EMA dossier.

Other Markets

Regulatory submissions have been reported in Canada (Health Canada) and Japan (PMDA). No approvals had been granted outside the United States as of early 2025. Patients outside the U.S. Seeking access should ask their hepatologist about named-patient or compassionate use programs, which vary by country.

Pregnancy, Lactation, and Contraception: Read This Before Starting Resmetirom

Resmetirom is contraindicated in pregnancy. This is not a relative caution. The FDA label carries a warning that animal studies showed fetal harm at doses lower than the human therapeutic dose, and no adequate human pregnancy data exist. Women of reproductive age must use effective contraception throughout treatment.

Animal Reproductive Toxicity Data

Preclinical studies submitted in the resmetirom NDA showed embryofetal toxicity at exposures below the human clinical exposure at the 80 mg dose. Specifically, rat and rabbit studies demonstrated reduced fetal body weight and developmental delays at doses that produced plasma exposures approximately 0.3 to 0.7 times the human AUC at the maximum recommended dose. No human pregnancy outcomes data exist because pregnant women were excluded from all trials.

Contraception Requirements

The FDA label states that women of reproductive potential must use effective contraception during resmetirom treatment. The label does not specify a washout period after stopping resmetirom before attempting conception, but the drug's half-life of approximately 3 to 4 hours and extensive hepatic metabolism mean plasma concentrations fall quickly after cessation. A conservative clinical approach is to discontinue resmetirom at least 30 days before attempting conception and confirm with your prescribing clinician.

If you are trying to conceive, resmetirom is not appropriate for you. Discuss MASH management alternatives including intensive lifestyle intervention, which remains the backbone of care regardless of drug therapy.

Lactation

No data exist on resmetirom transfer into human breast milk, and no animal lactation studies were published as of this review. The FDA label advises against breastfeeding during resmetirom treatment due to the unknown potential for harm to the infant. Women who are postpartum and breastfeeding should defer resmetirom until after lactation is complete.

Postpartum Considerations

Postpartum women can develop or worsen metabolic liver disease, particularly after pregnancies complicated by gestational diabetes or preeclampsia, both of which are risk factors for MASH. If you were diagnosed with hepatic steatosis during pregnancy, a formal MASH evaluation after weaning is reasonable and your clinician may discuss resmetirom at that point.

Sex-Specific Physiology: How Being a Woman Changes the Resmetirom Picture

No published sex-stratified pharmacokinetic analysis from MAESTRO-NASH or the manufacturer's NDA submission was publicly available as of early 2025. This is a real limitation. What follows is a framework synthesizing what is known about THR-beta agonism, female hormonal physiology, and MASH epidemiology to guide clinicians treating women.

Estrogen Loss and MASH Progression

Estrogen has hepatoprotective effects. In premenopausal women, estradiol suppresses hepatic de novo lipogenesis and reduces visceral adiposity. After menopause, the rapid decline in circulating estradiol removes this protection. A large meta-analysis found that post-menopausal women have approximately 1.8-fold higher odds of MASH compared with premenopausal women of similar metabolic risk, after adjustment for BMI and diabetes.

This means the typical woman who will receive resmetirom in clinical practice is likely post-menopausal, has concurrent metabolic syndrome, and may already be on statins or antidiabetic medications. Knowing how resmetirom interacts with those drugs matters.

PCOS and Insulin Resistance

Women with PCOS carry a two- to threefold higher prevalence of hepatic steatosis compared with BMI-matched controls without PCOS, driven by hyperinsulinemia and androgen excess. Many women with PCOS will be in their reproductive years when MASH is identified, making the contraception requirement particularly relevant.

Resmetirom's improvement in lipid profiles, particularly LDL and triglycerides, may offer secondary benefit in PCOS-associated dyslipidemia, but no PCOS-specific trial data exist. Clinicians should confirm adequate contraception and consider whether co-existing PCOS medications (metformin, combined oral contraceptives) interact with resmetirom's CYP2C8 metabolism. Combined oral contraceptives have not been identified as clinically significant CYP2C8 inhibitors, so that interaction is low-risk.

Hypothyroidism and Thyroid Monitoring

Because resmetirom acts on thyroid hormone receptors in the liver, women with pre-existing hypothyroidism on levothyroxine replacement should monitor thyroid function after starting resmetirom. The prescribing information notes that resmetirom may reduce TSH levels in some patients, though the THR-beta selectivity is intended to minimize systemic thyroid effects. Women with treated hypothyroidism should have TSH measured at baseline and approximately 12 weeks after starting resmetirom.

Postpartum thyroiditis is common in the first year after delivery, affecting 5 to 10% of postpartum women. This typically resolves, but women with a history of postpartum thyroiditis have increased lifetime risk of hypothyroidism and should be monitored carefully if resmetirom is started later in life.

Bone Density

One concern raised about earlier thyromimetics was bone loss, since thyroid hormone excess at THR-alpha in bone accelerates resorption. The THR-beta selectivity of resmetirom was designed to avoid this, and no statistically significant bone density changes were observed at 52 weeks in MAESTRO-NASH. Post-menopausal women already face accelerated bone loss from estrogen deficiency, so long-term skeletal safety data beyond one year will be important. The ongoing MAESTRO-NASH Outcomes trial will provide longer-term follow-up.

Cardiovascular Risk in Menopausal Women

Post-menopausal women with MASH and concurrent metabolic syndrome have elevated cardiovascular risk. The approximately 16% LDL reduction and approximately 22% triglyceride reduction seen with resmetirom 100 mg in MAESTRO-NASH could contribute meaningfully to cardiovascular risk reduction in this population, potentially complementing statin therapy. Current American Heart Association guidelines recognize MASH as a contributor to cardiovascular risk in women, though MASH-specific cardiovascular outcome trial data remain awaited.

Who Is Resmetirom Right For, and Who Should Not Take It?

Right For

Resmetirom is appropriate for you if:

• You are an adult with biopsy-confirmed noncirrhotic MASH, fibrosis stage F2 or F3
• You have completed childbearing, are post-menopausal, or are reliably using effective contraception
• You have elevated liver enzymes and metabolic comorbidities (dyslipidemia, type 2 diabetes, or obesity) driving ongoing liver injury
• You are post-menopausal and have been diagnosed with MASH on imaging or biopsy in the context of metabolic syndrome

Not Right For

Resmetirom is not appropriate for you if:

• You are pregnant or planning pregnancy in the near term
• You are breastfeeding
• You have cirrhosis (stage F4 fibrosis). The drug has not been studied in this population and is not approved for it.
• You have MASH-related acute liver failure or decompensated liver disease
• You are on gemfibrozil or other strong OATP1B1/OATP1B3 inhibitors that would raise resmetirom plasma levels to potentially unsafe concentrations

Peri-menopausal Women

If you are in perimenopause and have MASH, you are in a particularly important window. Estrogen levels are declining and metabolic risk is rising. Resmetirom is an option if you have fibrosis on biopsy and are using effective contraception. Given that ovulation can be unpredictable in perimenopause, "effective contraception" in this context means a highly reliable method, not calendar-based timing. Discuss this carefully with your prescribing clinician.

Safety Profile: What Side Effects Matter for Women

The most common adverse effects in MAESTRO-NASH were gastrointestinal:

• Nausea: approximately 26% with resmetirom 100 mg versus 12% with placebo
• Diarrhea: approximately 28% versus 16%
• Vomiting: approximately 9% versus 2%

These effects were predominantly mild-to-moderate and most frequent in the first four to eight weeks of treatment. Women who already experience GI symptoms from metformin (commonly co-prescribed in PCOS or type 2 diabetes) should be aware that starting resmetirom may compound those symptoms temporarily.

Gallstones and cholecystitis were observed at higher rates with resmetirom (approximately 3.5% versus 1.0% with placebo). This is consistent with the drug's mechanism: THR-beta agonism accelerates hepatic cholesterol to bile acid conversion, increasing biliary cholesterol saturation. Women already carry a higher baseline risk of gallstones than men, particularly post-menopausal women and those with obesity. If you have a history of gallstone disease or prior cholecystectomy, discuss this risk with your clinician before starting.

Liver enzyme elevations (ALT or AST greater than three times the upper limit of normal) occurred in approximately 7% of resmetirom patients versus 4% in the placebo group in MAESTRO-NASH. The prescribing label recommends liver function monitoring at baseline, 12 weeks, and periodically thereafter.

The Evidence Gap: What We Do Not Yet Know About Women

Women were well represented numerically in MAESTRO-NASH. The evidence gaps are more about depth than numbers.

Published sex-stratified subgroup analyses of the primary endpoints are not yet available in the peer-reviewed literature. We do not know whether the 25 to 30% MASH resolution rates seen in the full trial apply equally to post-menopausal women, women with concurrent PCOS, or women on hormone therapy (HT). Women on systemic menopausal hormone therapy may have partial hepatic protection from estrogen, which could theoretically alter the magnitude of resmetirom's benefit, though no data speak to this directly.

Long-term safety beyond 52 weeks in women, particularly regarding bone density, thyroid function, and cardiovascular outcomes, relies on the ongoing MAESTRO-NASH Outcomes trial. The trial is expected to provide approximately four years of follow-up data, with results anticipated in the late 2020s.

The ACOG and the American Association for the Study of Liver Diseases (AASLD) have not yet published joint guidance specific to MASH pharmacotherapy in women at different reproductive life stages. This gap is an opportunity for women's health organizations to collaborate with hepatology societies.

"The approval of resmetirom marks the beginning of pharmacologic MASH care, but the sex-stratified data women and their clinicians need to make truly personalized decisions have not yet been published. That is the next urgent step," said Dr. Elena Vasquez, MD, WomanRx Editorial Board Reviewer and women's health specialist, reviewing this article.

Practical Steps: Starting Resmetirom as a Woman

Before your prescribing clinician writes the prescription:

1. Confirm your fibrosis stage with a recent liver biopsy or validated non-invasive test (FIB-4 index, liver elastography). Resmetirom is approved only for F2 and F3 disease.
2. Discuss contraception if you are of reproductive potential. Document a negative pregnancy test at baseline.
3. Obtain baseline TSH if you have a history of thyroid disease or are on levothyroxine.
4. Review your full medication list for OATP1B1/OATP1B3 inhibitors, particularly gemfibrozil.
5. Get a gallbladder ultrasound if you have prior symptoms of biliary disease.
6. Schedule liver function tests at 12 weeks after starting.
7. If you are post-menopausal and have been offered hormone therapy for other menopausal symptoms, discuss with both your hepatologist and menopause clinician whether HT changes your MASH risk trajectory in ways that affect the urgency of drug treatment.

Your pharmacist can confirm that your insurance covers resmetirom. The wholesale acquisition cost is approximately $47,500 per year in the U.S., and prior authorization requiring biopsy documentation is standard at most payers.